Physician profile
Samuel S Bailey
NPI 1396912911
$1,504.15
in general payments reported to CMS, 2019-2025
13 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Plastic Surgery Within The Head & Neck provider received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $80.22 · 2021: $266 · 2022: $200 · 2023: $258 · 2024: $246 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $461.42 | 2019-2025 | Dupixent |
| Genzyme Corporation | $395.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $232.91 | 2021-2025 | Nucala |
| Optinose US, INC. | $169.43 | 2019-2022 | |
| Intersect Ent, INC. | $37.78 | 2019-2020 | |
| Aerin Medical INC. | $34.35 | 2024 | |
| Medtronic, INC. | $33.11 | 2021-2023 | Sinuva |
| Acclarent, INC | $32.84 | 2020-2023 | Acclarent Aera |
| Stryker Corporation | $26.91 | 2019-2020 | |
| Baxter Healthcare | $25.50 | 2024 | Perclot |
| Astrazeneca Pharmaceuticals LP | $21.08 | 2025 | Tezspire |
| Hikma Pharmaceuticals USA | $18.70 | 2024 | Ryaltris |
| Smith+Nephew, INC. | $15.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.